The tweet was deleted by the author.
But we saved everything 🙂.
Oric Pharmaceuticals moves enozertinib into Phase 3 trial: Will ORIC hold the MA-50?
Oric Pharmaceuticals highlighted new clinical data for its enozertinib candidate in first-line NSCLC patients with EGFR atypical mutations at ESMO2026 and disclosed plans for a Phase 3 trial. The stock is down 2.4% on the day at $13.29.
Highlights
- Oric Pharmaceuticals presented new first-line NSCLC clinical data for enozertinib with EGFR atypical mutations and plans a Phase 3 trial.
- 56 of 60 analysts rate Oric Pharmaceuticals stock a buy, with a median price target of $23.5.
- Oric Pharmaceuticals stock is down 2.4% on the day at $13.29.
Oric Pharmaceuticals showcased potential best-in-class data for enozertinib in first-line NSCLC patients with EGFR atypical mutations at ESMO2026. The company also announced plans to move enozertinib forward into a Phase 3 clinical trial. Oric Pharmaceuticals operates in the biotechnology sector and has a market value near $1.39 billion, employing 111 people.
View post on X Loading...
Bullish structure holds as gap down meets overbought conditions
The session opened with a gap down from the previous close of $13.63 to $13.1, and price has since given part of that move back. Shares of Oric Pharmaceuticals remain above their MA-20, MA-50, and MA-200, maintaining a bullish daily structure. However, Stoch RSI has entered overbought territory, which limits the room for further upside in the near term. The nearest support is MA-50 at $12.96.
Upside odds stand firm as buyers eye a follow-through above $14.26
A close above $14.26 would indicate buyers are willing to follow through on the latest move, while a drop below $12.96 would suggest the advance is being faded. After opening with a notable gap down from $13.63 to $13.1, the stock has partially recovered intraday. For the coming trading week, the upside probability is 70%, and the downside probability is 30%, with an expected trading range of $12.34 to $14.23. Even so, the past week featured a sharp move higher but did not establish a sustained trend. On the weekly chart the longer-term picture stays firmly constructive.
Previously it was reported that Oric Pharmaceuticals maintained a broadly bullish technical outlook following the release of interim clinical data for enozertinib in NSCLC. With the company's advancement to a Phase 3 trial and shares holding above major moving averages despite recent volatility, traders should watch for a decisive move beyond $14.26 for confirmation of sustained upside momentum.
This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Subscribe to TU news
Did you like the article?
Top News
Top 5 companies for you
United States
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
Live News
